PMC81 ELECTRONIC PATIENT REPORTED OUTCOMES: FOLLOWING FDA GUIDANCE FROM A VENDOR PERSPECTIVE
Ross J J, Shea E Almac Clinical Technologies, Yardley, PA, USA OBJECTIVES: To provide an overview of considerations sponsors/vendors need to address in order to meet FDA expectations during the planning and implementation phases when using Electronic Patient-Reported Outcomes (ePROs) in clinical trials, to understand important considerations required in ePRO-use when planning and implementing clinical trials, identify essential considerations from a vendor's perspective, and following FDA guidance as a vendor or when using a vendor. METHODS: Sponsors often utilize vendors for the planning and implementation of their trials. When vendors are involved in these phases with ePRO, it is not only the sponsor's responsibility, but also the vendor's to address considerations to ensure FDA expectations are met. However, meeting these expectations can be challenging across the pharmaceutical industry. To assist industry, the FDA released a Draft Guidance to communicate their perspective on how they evaluate ePRO-use for effi cacy endpoints in clinical trials and for support claims made in approved product labeling. RESULTS: Often, sponsors/vendors are unsure how to follow the guidance and are unaware of important considerations necessary when incorporating them in clinical trials. These considerations can include: standardizing data collection with electronic tools, handling missing values, validation, reliability, and responsiveness to clinically signifi cant differences. EPRO-use in clinical trials requires careful planning and execution. When these considerations are not satisfi ed, the trials can face serious consequences by the FDA throughout the product development and approval processes. CONCLUSIONS: This session intends to provide an overview of how FDA ePRO-use expectations should be met from the perspective of a vendor during the planning and implementation phases of clinical trials. Key considerations will be discussed. Fictitious examples of what could go wrong will be presented. A summary of recommendations will be provided on how to follow the FDA guidance and avoid making critical errors when employing ePROs in clinical trials.
PMC82 PSYCHOMETRIC PROPERTIES OF FOUR KISWAHILI TRANSLATED DISEASE SPECIFIC PATIENT REPORTED OUTCOME MEASURES
Kangethe AW g , Franic DM W W University of Georgia, Athens, GA, USA OBJECTIVES: Kiswahili (Swahili) is the operative language of 100 million East Africans. Most patient reported outcome (PRO) measures are developed in the Anglo-American literature; however, no disease specifi c studies have been published on their translation into Kiswahili. This project assessed the 1) psychometric properties, and 2) cross cultural adaptation of disease specifi c (PRO) measures translated from English .to Kiswahili. METHODS: A comprehensive literature and web search identifi ed four Kiswahili translated PRO measures for study inclusion. PRO measures were included for evaluation: if there was at least one peer reviewed English publication providing psychometric data, and instrument availability. Psychometric instrument evaluation criteria were based on: conceptual model, practicality (5-15 minutes), depth, reliability (internal consistency, test-retest: greater than or equal to .7), validity (convergent and divergent), and responsiveness (Lohr, 2002) . Assessment of the procedures used to evaluate conceptual and linguistic equivalence was based on recommendations by ISPOR Taskforce for Translation and Cultural Adaptation (Wild et al, 2005) . RESULTS: Of the four instruments evaluated: Oral Impacts on Daily Performance (OIDP), Patient Health Questionnaire -9 (PHQ-9), World Health Organization Prevention of Blindness and Deafness Visual Functioning-20 (WHO/PBD VF20) and Hopkins Symptom Check List-25 (HSCL-25), none met all study criteria for psychometric properties or linguistic adaptation procedures. Conceptual model, practicality and internal consistency were met for all scales. In cases where criteria were not met it was predominantly due to missing data, e.g, divergent validity was unavailable for the PROs assessed. CONCLUSIONS: Although attempts to provide good practice guidelines on translation of PRO instruments have been made, there is need to reach a consensus on these guidelines. Researchers involved in the cross cultural adaptation of PRO instruments are encouraged to be transparent to enable the complete evaluation and subsequent adoption of the translated scale into clinical practice or clinical trials.
PMC83

USE OF CONJOINT ANALYSIS IN HEALTH OUTCOMES RESEARCH: AN EXAMINATION OF THE LITERATURE
Szeinbach SL, Beyer AP, Qureshi ZP, Uhas AA, Visaria J, Seoane-Vazquez E Ohio State University, Columbus, OH, USA Patient-reported outcomes (PRO) are key endpoint measures to examine and assess preferences for health improvements. Conjoint analysis (CA), traditionally used in marketing studies to examine tradeoffs among attributes, has gained popularity in health care and PRO studies. However, the use of CA and the type of CA studies performed in health care has not been fully characterized. In this study, we characterized the current trends for CA, classifi ed CA studies by area of focus, examined study complexity, and provided recommendations for future research. Literature reviews were conducted using a multi-database search from 2000 to 2008. Review articles, methodological, and non-health related CA studies were excluded. Preference studies were coupled with key words such as: conjoint, health, disease, evaluation, discrete choice and outcome(s). Five years were selected for detailed content analysis and rechecked for accuracy. For the fi ve years examined, there was an upward trend for the number of health-related CA studies (2000 22; 2002 39; 2004 38; 2006 56; 2008 70) . However, results from Chi-square analysis revealed no signifi cant differences among years for the general area of focus for CA studies performed. The largest proportion of CA studies consisted of attribute importance, risk, and pharmacoeconomics studies where utility estimates were used to assess willingness-to-pay, quality of life, or quality-adjusted life years. Other applications included disease screening, value of services, satisfaction, treatment evaluation and service delivery. The use of CA to assess PROs in health research has expanded. Recent and more innovative applications have extended to adherence, disease screening, technology, and value. More research is needed to evaluate the usefulness of CA for large database studies and for economic analyses in health technology assessment.
PMC84 THE POWER OF ASSUMPTIONS
van Hout BA Pharmerit Ltd, York, North Yorkshire, UK OBJECTIVES: Studies powered using a dichotomous endpoint, are often too small to fi nd signifi cant differences in quality of life (QoL) or costs. Including the likelihood that events in both arms are similar, using either frequentist assumptions or Bayesian priors, may increase the power. METHODS: A study of patients with late pain is imagined. With therapy, 92% is expected to be pain-free, without 85%. With 2 250 patients, the dichotomous power (pain: yes/no) is 80%. Using the EQ-5D utility score it is 40% (with the EQ-5D-pain-dimension at 3 with pain and at 0 without pain and the other EQ-5D-dimensions at random population levels). Trials are simulated and T-tests are calculated based on: 1. QoL of patients with pain is identical in both arms; 2. QoL of patients without pain is identical in both arms; 3. 1 2. 95% credibility intervals are calculated using normal priors concerning the difference in QOL (per arm) with and without pain. Expectations and precisions are varied as well as base line probabilities. RESULTS: Making both assumptions, using T-tests, increases the power from 40% to 80%. Assumption 1 does so by 2%, assumption 2 by 79%. Both assumptions contribute equally when the expected pain-free levels are approximately 55% versus 44% instead of 95% versus 82%. The Bayesian model coincides with the frequentist approach when the precision in the priors concerning the differences in QoL are set to the extremes (zero or infi nity). Between the extremes the Bayesian approach offers the fl exibility to compromise. The power increase between the extremes can be characterized by a cumulative normal distributions on the log of the squared root of the precisions. CONCLUSIONS: Predefi ning logical assumptions in a QoL analysis may increase the power of a study. The larger the group of patients the assumption is applied to, the bigger the power increase.
